EUVIMEDEUVIMED entdecken
Crossref

Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy

Shinyoung Lee, Hyehyun Jeong, Eunju Shin, Sae Byul Lee, Jae Ho Jeong, Hee Jin Lee, Gyungyub Gong, Min-Ju Kim, Hee Jeong Kim, Jong Won Lee, Byung-Ho Son, Jaewon Hyung und 3 weitere

Clinical Breast Cancer · 2026

DOI: 10.1016/j.clbc.2025.09.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2026. Verfasst von Shinyoung Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Capecitabine, Neoplasm, Residual, Neoplasm Recurrence, Local. Die Arbeit nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In early triple-negative breast cancer (TNBC), surgery following neoadjuvant chemotherapy (NAC) is standard. Adjuvant capecitabine has shown survival benefits in patients with residual disease; however, data remain limited regarding the subgroups that benefit most, particularly when stratified by residual cancer burden (RCB), a key prognostic indicator post-NAC. METHODS: Patients with early TNBC and residual disease following NAC (Feb 2008-Dec 2021) were retrospectively included. After propensity score matching to balance baseline characteristics, recurrence-free survival (RFS) was compared between patients who received adjuvant capecitabine and those who did not. RESULTS: Of 828 eligible patients, 631 were included in the final propensity score matched analysis (222 capecitabine; 409 observation). Median ages were 48 years (range, 40-56) and 50 years (range, 41-56) in the observation and capecitabine groups. RCB distribution was comparable between groups: RCB-I (10% vs. 11%), RCB-II (68% in both), and RCB-III (22% vs. 21%). RCB was prognostic across the cohort, with 3-year RFS rates of 92.2%, 73.6%, and 43.3% for RCB-I, -II, and -III, respectively. Adjuvant capecitabine improved RFS in RCB-III (HR, 0.6; 95% CI, 0.3-0.9; P = .02), but not in RCB-I (HR, 1.1; 95% CI, 0.2-6.5; P = .93) or RCB-II (HR, 0.9; 95% CI, 0.7-1.4; P = .84). In RCB-III, distant metastasis occurred less frequently in the capecitabine group compared with the observation group (34.0% vs. 62.9%). CONCLUSION: Adjuvant capecitabine was most beneficial in patients with RCB-III disease, primarily through a reduction in distant metastasis. These findings support its selective use in high-risk TNBC populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsCapecitabineNeoplasm, ResidualNeoplasm Recurrence, LocalHumansFemaleMiddle AgedNeoadjuvant TherapyAdultChemotherapy, AdjuvantRetrospective StudiesPrognosisTumor BurdenPropensity ScoreFollow-Up Studies

Stichwörter der Autor:innen

CapecitabineDistant disease-free survival (DDFS)Overall survival (OS)Pathologic complete response (pCR)Recurrence-Free Survival (RFS)

Substanzen

Capecitabine

Autor:innen und Institutionen

  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Department of Surgery, College of Medicine, Kyung Hee University, Seoul, South K…
  • Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: newstar@amc.seoul.kr.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: jaeho.jeong@amc.seoul.kr.
  • Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
  • Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Zitieren

APA

Lee, S., Jeong, H., Shin, E., Lee, S. B., Jeong, J. H., Lee, H. J., Gong, G., Kim, M. J., Kim, H. J., Lee, J. W., Son, B. H., Hyung, J., Ahn, J. H., Jung, K. H., & Kim, S. B. (2026). Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.09.006

Vancouver

Lee S, Jeong H, Shin E, Lee SB, Jeong JH, Lee HJ, et al. Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy. Clinical Breast Cancer. 2026. doi:10.1016/j.clbc.2025.09.006

BibTeX
@article{Lee2026,
  author = {Lee, Shinyoung and Jeong, Hyehyun and Shin, Eunju and Lee, Sae Byul and Jeong, Jae Ho and Lee, Hee Jin and Gong, Gyungyub and Kim, Min-Ju and Kim, Hee Jeong and Lee, Jong Won and Son, Byung-Ho and Hyung, Jaewon and Ahn, Jin-Hee and Jung, Kyung Hae and Kim, Sung-Bae},
  title = {Clinical Benefit of Adjuvant Capecitabine According To Residual Cancer Burden in Patients With Triple-Negative Breast Cancer With Residual Disease Following Neoadjuvant Chemotherapy},
  journal = {Clinical Breast Cancer},
  year = {2026},
  doi = {10.1016/j.clbc.2025.09.006}
}
Kostenlos starten →